BRIEF-U.S. FDA expands approval of Imbruvica for treatment of adult patients with cGVHD
August 02, 2017 at 11:39 AM EDT
* Expanded the approval of Imbruvica (ibrutinib) for the treatment of adult patients with chronic graft versus host disease
